Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of itolizumab plus corticosteroids as initial treatment for acute graft-versus-host disease
MOH_2022-05-24_010823Phase 3Recruiting
- Sponsor
- Equillium, Inc.
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Acute Graft-Versus-Host Disease (aGvHD) comparing Itolizumab + systemic corticosteroids with Placebo + systemic corticosteroids (2 arms). Primary endpoint: Early disease response. Started May 2022; status: recruiting.
02
Drugs
itolizumab
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on MOH_2022-05-24_010823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-05-24_010823.